Molecular Partners publishes Ph 1 MP0317 data in Nature Cancer
“The Phase 1 data published in Nature Cancer demonstrate the promising ability of MP0317 to turn cold tumors hot by locally modulating the tumor microenvironment, while avoiding systemic toxicities often seen with untargeted CD40 agonists. These data support further clinical evaluation of MP0317 in combination with other immunotherapy modalities, such as checkpoint inhibitors,” said coordinating investigator Philippe Cassier, M.D., Ph.D., of the Centre Léon Bérard in Lyon, France. “We are currently enrolling patients with cholangiocarcinoma in an investigator-initiated Phase 2 study of MP0317 in combination with standard of care chemotherapy and anti-PDL1 therapy, led by Prof. Christophe Borg, and look forward to assessing its clinical benefit for patients.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.